Eurotherm June/July 2010 Newsletter

3
Congratulations to Hungary, Northern Ireland and Russia for obtaining Ethical Approval for the Eurotherm3235 Trial. This is great news and we look forward to working with you in the near future. Well done to Belgium, Estonia, Germany, Italy and Southern Ireland who have all submitted documents to their Ethical Committees recently and are awaiting ethical opinion. oing South, East and West G The following Sites have received hospital approvals and are ready to start recruitment. Royal Berkshire Hospital, Reading, UK – Principal Investigator Dr Carl Waldmann, Dr Chris Danbury, Nicola Jacques, Heather Prowse, Jane Atkinson and Andy Pells. Leeds General Infirmary, Leeds, UK – Principal Investigator Dr Justin McKinlay, Zoe Beardow, Stuart Elliot and Karen Griffiths Royal Hallamshire Hospital, Sheffield, UK- Principal Investigator Dr David Turnbull, Dr John Andrzejowski, Dr Patrick Dobbs, Dr George Espen, Dr Stefan Jankowski, Dr James Hoyle, Dr Andrew Davidson and Alastair Smith. elcome on board W Flights and Registration to the ESICM or ISICEM meeting will be awarded to the best recruiting centre each year. rize! P We have recruited 4 patients to the trial. More sites are now enrolled and are screening patients. ecruitment R We are pleased to announce that we have a new 24-hour telephone Hotline. If you are experiencing problems with randomising a patient, call the Hotline: +0044 (0)7834416962. For all other matters, please call the Eurotherm office. H otline EUROTHERM3235 Trial Newsletter June/July 2010, Issue 3

Transcript of Eurotherm June/July 2010 Newsletter

Page 1: Eurotherm June/July 2010 Newsletter

Congratulations to Hungary, Northern Ireland and Russia for obtaining Ethical Approval for the Eurotherm3235 Trial. This is great news and we look forward to working with you in the near future.

Well done to Belgium, Estonia, Germany, Italy and Southern Ireland who have all submitted documents to their Ethical Committees recently and are awaiting ethical opinion.

oing South, East and WestG

The following Sites have received hospital approvals and are ready to start recruitment.

Royal Berkshire Hospital, Reading, UK – Principal Investigator Dr •Carl Waldmann, Dr Chris Danbury, Nicola Jacques, Heather Prowse, Jane Atkinson and Andy Pells.

Leeds General Infirmary, Leeds, UK – Principal Investigator Dr Justin •McKinlay, Zoe Beardow, Stuart Elliot and Karen Griffiths

Royal Hallamshire Hospital, Sheffield, UK- Principal Investigator Dr •David Turnbull, Dr John Andrzejowski, Dr Patrick Dobbs, Dr George Espen, Dr Stefan Jankowski, Dr James Hoyle, Dr Andrew Davidson and Alastair Smith.

elcome on boardW

Flights and Registration to the ESICM or ISICEM meeting will be awarded to the best recruiting centre each year.

rize!P

We have recruited 4 patients to the trial. More sites are now enrolled and are screening patients.

ecruitmentR

We are pleased to announce that we have a new 24-hour telephone Hotline. If you are experiencing problems with randomising a patient, call the Hotline: +0044 (0)7834416962. For all other matters, please call the Eurotherm office.

H otline

EUROTHERM3235Trial NewsletterJune/July 2010, Issue 3

Page 2: Eurotherm June/July 2010 Newsletter

Dr. Anthony Gordon, Site Principal Investigator, Research lead for Charing Cross critical care

“Charing Cross Hospital is part of Imperial College Healthcare Trust, the largest Trust in England and also an Academic Health Science Centre. Charing Cross hospital itself is situated in Hammersmith and is the Neurosciences Centre for West London. The ICU is a general unit with dedicated neuroscience critical care beds.

We have the capacity for 27 beds; however, we have the same problem as many other hospitals in the South -staff recruitment- so at present we are only running 18 critical care beds. In October this year a designated major trauma unit will also be opening on the St Mary’s site in Paddington.

We have a well established Clinical Research and Audit Team who cover 57 Critical Care beds over three sites, managed by Maie Templeton. At present we have three research nurses, Robert Wilson, Claire Gibbs and Laura Mountford, and they are supported by the clinical audit team; Mike, Kim, Frances, Dena and Karleen.

We are delighted to be one of the first centres outside of Scotland to participate in the Eurotherm study, and we are looking forward to having a long and productive relationship with the Eurotherm team. “

S ite feature Charing Cross Hospital

Jane Taylor, Eurotherm Research Nurse

“We are a large General Intensive Care Unit in Aberdeen Royal Infirmary with the capacity for 16 patients. We accept patient from all specialities and there is a Cardiac Intensive Care Unit working alongside us. As the most northern hospital in Scotland with a Neurosurgical Department we accept patients from the North East of Scotland, Highlands & Islands.

Our research team consists of 2 permanent full time nurses and one seconded post. These 3 posts cover a 7-day service encompassing Research, Follow-Up and Audit. The research nurses currently working within the team are Jane Taylor, Jenni Addison and Nicola Donald, we are a small but motivated team. Dr David Noble is our clinical lead, PI for Eurotherm and ICU Head of Service.

We look forward to recruiting our first of hopefully many patients for the Eurotherm Study.”

S ite feature Aberdeen RoyalInfirmary

Aberdeen, Scotland, UK

lmperial College, London Healthcare NHS Trust, UK

Page 3: Eurotherm June/July 2010 Newsletter

Q. When do I randomise my patient?

A. Patients should be randomised as soon as their ICP level rises above 20mmHg despite first line/stage 1 treatments (e.g. sedation, ventilation control etc.) In most cases the patient will receive a hypertonic treatment before randomisation, although this is not mandatory.

Q. I am not sure if more than one dose of hypertonic will be needed. Can I still randomise to EUROTHERM?

A. Yes. It is often difficult to predict who will develop more severe brain swelling. If I&E are met please randomise.

Please remember the EUROTHERM3235 Trial is a trial of titrated hypothermia to reduce raised ICP after brain trauma in adults with an abnormal brain CT scan.

Frequently asked questions will be listed shortly on the Eurotherm website.

F requently asked Questions

Neil Smith, Eurotherm Research Nurse

“We are a 10-bedded General Intensive Care Unit in Hull Royal Infirmary. We predominately accept acute presenting patients from all specialities with the exception of Cardiac surgery and work in tandem with our 12 bedded General High Dependency Unit. There is also a separate Neurosurgical High Dependency Unit of 9 beds. We act as a tertiary referral centre for Scarborough to the north, Scunthorpe and Grimsby to the south and York to the west.

Our research team consists of myself, covering the department of Anaesthesia and Critical Care across two hospital sites. Currently we only provide cover for a 9-5 weekday service. The PI for Eurotherm is Dr Andrew Gratrix, consultant in Intensive Care.

We are currently screening patients for the Eurotherm Study.”

S ite feature Hull Royal Infirmary

Edinburgh Clinical Trials Unit Central Office, University of Edinburgh Outpatients Building, Floor Two, Room D36 Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU

Tel: +44 131 5371131 / 5856 Fax: +44 131 5373851www.eurotherm3235trial.eu email: [email protected]

for your continued support of the Eurotherm trial, we really do appreciate all your hard work!

Thank youProfessor Peter Andrews’ video presentation on the Eurotherm3235 trial can be viewed online. Go to www.eurotherm3235trial.eu and click the link on the Useful Links and References page.

O nline Lecture

Hull, UK